Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells
Leukemia, Published online: 03 December 2019; doi:10.1038/s41375-019-0640-4Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells
Publication date: Available online 8 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Chakra P. Chaulagain, Julia M. Diacovo, Leah Elson, Raymond L. Comenzo, Christy Samaras, Faiz Anwer, Jack Khouri, Heather Landau, Jason ValentAbstractThere is paucity of literature regarding management of clonal plasma cell neoplasms in the recipients of solid organ transplant. This is a rare group of disorders which present difficulty in diagnosis and management. In this retrospective case series, we describe the clinical and pathologic characteristics of patients with AL amyloidosis and extramedullary plasmacytoma in...
ConclusionsMonoclonal antibodies with distinctly different targets can be safely combined in patients with AL and cardiac involvement. Patients experienced high rates of hematologic and cardiac response with combined anti-CD38 and anti-amyloid monoclonal antibody therapies. Further study of this combined approach is warranted.
Leukemia, Published online: 28 November 2019; doi:10.1038/s41375-019-0667-6IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features
Leukemia, Published online: 26 November 2019; doi:10.1038/s41375-019-0664-9Revisiting complete response in light chain amyloidosis
Leukemia, Published online: 22 November 2019; doi:10.1038/s41375-019-0655-xBone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis
ConclusionsIn summary, CyBorD showed a ≥VGPR rate of 53% with 26.5% achieving CR, which is similar to that seen in previous studies. In addition, MRD negativity assessed by MPF in patients with CR resulted in no difference on survival outcomes.
Leukemia, Published online: 06 November 2019; doi:10.1038/s41375-019-0619-1Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance
ConclusionOutpatient ASCT is a safe and feasible treatment strategy with low transplant-related mortality. Overall resource utilization is significantly lower than inpatient ASCT: however, this requires a multidisciplinary approach with close follow-up.
Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Cindy Varga, Viji Nair, Agnes Fogo, Samih Nasr, Bradley Godfrey, Felix Eichinger, Denis Toskic, Matthias Kretzler, Raymond L. Comenzo
Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Rubén Fernández, Ana Silva - Soto, Sara Muñiz, Ana Pilar Gonzalez, Angel Ramirez Payer, Arancha Bermudez, Francisco Taboada, Cristina Chamorro, Marlen Moran, Verónica Robles, Sara Sanchez, Juan Torres, Francisco Dominguez, Carlos Alberto Davalos, Alba Alvarez, Segundo Gonzalez, Javier Cepeda, Carmen Fernández, Esther González